Truist lowered the firm’s price target on Incyte (INCY) to $72 from $74 and keeps a Hold rating on the shares. Following the ...

Incyte's revenues continues to grow, with full-year 2024 revenues reaching $4.2 billion, driven by JAKAFI and OPZELURA. Click ...

The biopharmaceutical company announces positive results from two skin disease treatment studies. But Wall Street doesn’t ...

Shares of biopharmaceutical company Incyte Corporation (NASDAQ:INCY) fell 15.2% in the pre-market session after the company ...

Incyte (NASDAQ:INCY – Free Report) had its price target reduced by Truist Financial from $74.00 to $72.00 in a report issued on Tuesday,Benzinga reports. They currently have a hold rating on the ...

Shares of Incyte Corp. slid 8.62% to $62.01 Monday, on what proved to be an all-around positive trading session for the stock ...

Guggenheim lowered shares of Incyte (NASDAQ:INCY – Free Report) from a buy rating to a neutral rating in a report issued on Tuesday, Marketbeat Ratings reports. They currently have $92.00 price ...

In a report released today, Srikripa Devarakonda from Truist Financial reiterated a Hold rating on Incyte (INCY – Research Report), with a ...

William Blair downgraded Incyte (INCY) to Market Perform from Outperform.Light Up your Portfolio with Spark:Easily identify stocks' risks and ...

Incyte's povorcitinib met key Phase 3 trial endpoints in hidradenitis suppurativa, showing significant clinical response and a well-tolerated safety profile.

U.S. equities were mixed at midday, with positive news on retail sales eased continuing concerns about tariffs.

The latest international Siddhi Mahatole news and views from Reuters - one of the world's largest news agencies ...